Multicenter, Open-label, Extension Study to Characterize the Long-term Efficacy and Safety of Early Versus Delayed Treatment With Venglustat (GZ/SAR402671) in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Latest Information Update: 31 Dec 2023
At a glance
- Drugs Venglustat (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Registrational; Therapeutic Use
- Acronyms STAGED-PKD-EXT
- Sponsors Sanofi
- 03 Aug 2021 This trial has been completed in Netherlands, according to European Clinical Trials Database record.
- 30 Jul 2021 This trial has been completed in Germany, according to European Clinical Trials Database record
- 21 Jul 2021 Status changed from active, no longer recruiting to discontinued.(study was stopped after protocol specified interim analysis for futility of the Stage 1 of the EFC15392 study met the prespecified stopping rule based on the primary endpoint. )